IP Library Granted Patent US 12,329,774
Granted Patent B2
US 12,329,774 · App. 17/222,953 · Granted Jun 17, 2025

Method and composition for enhancing the quality and benefits of sleep

Inventors: Deanna J. Nelson (Raleigh, NC); James R. Komorowski (Trumbull, CT)
Assignee: BioLink Life Sciences, Inc.
A61K33/06A23L33/10A23L33/16A61K9/0019A61K9/0053A61K31/191A61P25/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,329,774
App. No.
17/222,953
Granted
Jun 17, 2025
Kind
B2
Abstract

Compounds, compositions and methods of making and using for enhancing the quality and benefit of sleep and/or wakefulness in a subject in need thereof.

Claims (12)

1. A composition comprising magnesium di-L-theanate:

wherein the magnesium di-L-theanate exhibits an optical rotation of 3-4°.

2. A method of improving sleep in a subject in need thereof, the method comprising the step of administering an effective amount of magnesium di-L-theanate, wherein the effective amount is about 20 mg/kg body weight, wherein the effective amount is sufficient to decrease sleep latency and/or increase length of sleep, wherein said magnesium di-L-theanate is a solid having a molecular structure of

an optical rotation of 3-4°, and contains 5.5-6.0% by weight magnesium and 94.0-94.5% by weight L-theanate.

3. The method of claim 2 , wherein the magnesium di-L-theanate is formulated for administration to a mammal.

4. The method of claim 3 , wherein the step for administration is administration by mouth.

5. A method of preparation for a magnesium di-L-theanate compound, comprising the steps of:

(a) Dissolving 2 mole equivalents of L-theanine and 1 mole equivalent of magnesium ethoxide in an aqueous alcohol solution, wherein the alcohol in said aqueous alcohol solution is ethanol or methanol;

(b) Allowing said solution to stir at ambient or elevated temperature until a clear solution is obtained;

(c) Removing volatile solvents from said clear solution by evaporation to provide a solid;

(d) Dispersing the solid in an immiscible solvent and removing said solvent by filtration to provide a solid filtrand of purified magnesium di-L-theanate;

(e) Drying said solid filtrand to remove residual solvents and provide purified magnesium di-L-theanate.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 5, 2023
From: NUTRITION 21, LLC
To: BIOLINK LIFE SCIENCES, INC.
Reel/Frame 064796/0258 →
SECURITY INTEREST Recorded Nov 9, 2021
From: NUTRITION 21, LLC
To: CAPITAL ONE, NATIONAL ASSOCIATION, AS AGENT
Reel/Frame 058060/0535 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 21, 2021
From: JDS THERAPEUTICS, LLC
To: NUTRITION 21, LLC
Reel/Frame 056933/0653 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 5, 2021
From: NELSON, DEANNA J.; KOMOROWSKI, JAMES R.
To: JDS THERAPEUTICS, LLC
Reel/Frame 055829/0497 →